中医药治疗Graves病:临床疗效、药理机制与挑战
该综述按PRISMA 2020检索2005至2025年PubMed、Web of Science、CNKI和万方数据库中评估中医药干预Graves病的随机对照试验。结果显示中药复方、单药及活性成分可能通过降低抗体水平、调节免疫稳态、诱导甲状腺滤泡细胞凋亡、调节肠道菌群及抗氧化抗炎等发挥治疗作用,与常规抗甲状腺治疗联用多数研究显示良好疗效。
要点
- 中医药联合常规抗甲状腺治疗在多数临床研究中显示对Graves病有良好疗效。
- 中药复方、单药及活性成分可能通过降低抗体、调节免疫和诱导凋亡等发挥作用。
- 未来需明确免疫调节的精确分子机制、识别有效活性成分并建立标准化方案。
核心结论
- 中医药是有前景的Graves病治疗策略,与常规抗甲状腺治疗联用多数临床研究显示良好疗效。
研究设计与样本
- 纳入文献按证据性质分为临床证据(RCT)、临床前体内外证据、计算预测(网络药理学)和传统使用记录五个层级。
主要发现
- 中药复方、单药及活性成分可能降低抗体水平、调节免疫稳态、诱导甲状腺滤泡细胞凋亡、调节肠道菌群并发挥抗氧化抗炎作用。
- 涉及的信号通路和靶点包括Bcl-2/Bax、Fas/FasL、Caspase-3/Caspase-8、PI3K/Akt和Raf/MEK/ERK等。
临床怎么用
- 临床可考虑在常规抗甲状腺治疗基础上联用中医药,多数临床研究显示良好疗效。
局限性
- 未来需阐明免疫调节的精确分子机制、识别发挥疗效的具体活性成分并建立标准化方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Graves' disease (GD) is a common autoimmune disorder affecting the thyroid gland and is the most common cause of hyperthyroidism and thyrotoxicosis. Given the limitations of current conventional antithyroid therapy for GD, including side effects and relapse concerns, exploring alternative therapeutic options, such as Traditional Chinese Medicine (TCM), is of clinical interest. TCM, with its advantages of multi-component, multi-target actions and relatively mild side effects, has become a promising alternative therapy for GD. AIM OF THE STUDY: This review aims to systematically discuss the clinical efficacy of Chinese herbal formulas, single herbs, and their isolated active constituents reported in the literature over the past two decades for the treatment of GD, summarize the molecular mechanisms of treatment, conduct a safety evaluation, clarify the potential advantages of TCM in GD therapy, and provide insights for future TCM-based GD treatment strategies. MATERIALS AND METHODS: This review was conducted according to the PRISMA 2020 statement. We searched PubMed, Web of Science, CNKI, and Wanfang Data from January 2005 to December 2025 for randomized controlled trials (RCTs) evaluating TCM interventions for Graves 'disease. The references included in this review were classified into five hierarchical levels according to their evidentiary nature and usage: clinical evidence (RCTs) for clinical efficacy evaluation, preclinical in vivo and in vitro evidence for mechanistic support, computational predictions (network pharmacology) for bioactive compound annotation, and traditional-use records for ethnopharmacological background. RESULTS: Numerous studies have shown that Chinese herbal formulas, single herbs, and their isolated active constituents have potential therapeutic benefits in the management of GD. These benefits are associated with reducing antibody levels, modulating immune homeostasis, inducing apoptosis of thyroid follicular cells, regulating gut microbiota, exerting antioxidant and anti-inflammatory actions, among others. The reported signaling pathways and targets include Bcl-2/Bax, Fas/FasL, Caspase-3/Caspase-8, PI3K/Akt and Raf/MEK/ERK, among others. CONCLUSIONS: TCM, backed by extensive clinical experience, represents a promising therapeutic strategy for GD. When combined with conventional antithyroid therapy, TCM has demonstrated favorable efficacy in the majority of clinical studies on GD. Future research should prioritize elucidating the precise molecular mechanisms of immune regulation, identifying the specific active constituents responsible for efficacy, and establishing standardized protocols to strengthen the theoretical and scientific foundation for TCM in GD treatment.
引用
- Su L, Guo D, Su B, et al. Traditional Chinese medicine for Graves' disease: Clinical efficacy, pharmacological mechanisms, and challenges. J Ethnopharmacol. 2026. PMID: 42826809. doi:10.1016/j.jep.2026.122443
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。